financetom
Business
financetom
/
Business
/
With Meta And Microsoft Boosting Capex, Oracle's (ORCL) Rally Points To Major AI Tailwinds
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
With Meta And Microsoft Boosting Capex, Oracle's (ORCL) Rally Points To Major AI Tailwinds
Aug 14, 2025 8:58 AM

Oracle Corp ( ORCL ) shares are trading higher Thursday morning as investors digest recent news highlighting the company’s aggressive push into artificial intelligence against a backdrop of strategic cost controls.

What To Know: Analyst optimism has been a significant driver for the stock over the past month, with Bernstein raising its price target to $308, projecting Oracle could become the fourth-largest global hyperscaler fueled by its cloud infrastructure growth.

Piper Sandler and Bank of America also issued favorable outlooks, with BofA increasing its target to $295, citing massive AI-related spending from tech giants like Microsoft and Meta as a key demand signal for Oracle’s services. The company recently secured a major deal to supply cloud infrastructure to OpenAI.

Furthering its AI ambitions, Oracle this week unveiled a new intelligent Electronic Health Record system, using voice commands and AI to streamline clinical workflows and challenge competitors in the healthcare space. This wave of positive developments was tempered, however, by reports of layoffs within its cloud unit.

The job cuts are seen as a move to manage soaring costs associated with building out its AI infrastructure, mirroring similar measures across the tech sector. While bullish on Oracle’s long-term AI strategy, some analysts remain cautious.

Bank of America, meanwhile, maintained a Neutral rating, citing a high valuation and uncertainty over how quickly the significant AI investments will translate into substantial revenue growth.

Benzinga Edge Rankings: According to Benzinga Edge stock rankings, Oracle demonstrates exceptional Momentum with a score of 92.95, indicating strong recent price performance and positive investor sentiment. The stock also shows a solid Growth profile, scoring 63.32, which suggests healthy expectations for future expansion in revenue and earnings.

The stock’s Value score is otherwise notably low at 12.83. This suggests that, based on current fundamental metrics, ORCL is considered expensive, aligning with analyst concerns about its high valuation following its recent run-up in price.

Price Action: According to data from Benzinga Pro, ORCL shares are trading higher by 0.34% to $244.96 Thursday morning. The stock has a 52-week high of $260.87 and a 52-week low of $118.86.

Read Also: Anthropic Gives Claude To US Government For $1 As OpenAI, Others Vie For Federal Influence

How To Buy ORCL Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Oracle’s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medtronic to separate diabetes business, WSJ reports
Medtronic to separate diabetes business, WSJ reports
May 26, 2025
May 21 (Reuters) - Medical device maker Medtronic ( MDT ) plans to separate its diabetes business into a stand-alone company, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. ...
Johnson & Johnson's Darzalex Faspro Secures Positive Vote From FDA's Oncologic Drugs Advisory Committee
Johnson & Johnson's Darzalex Faspro Secures Positive Vote From FDA's Oncologic Drugs Advisory Committee
May 26, 2025
05:03 AM EDT, 05/21/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee has voted in favor of Darzalex Faspro's benefit-risk profile for the treatment of adult patients with high-risk smoldering multiple myeloma. The company said the committee's recommendation was based one positive progression-free survival and clinical...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
China's Baidu reports first-quarter revenue tops estimates, signalling advertising recovery
China's Baidu reports first-quarter revenue tops estimates, signalling advertising recovery
May 26, 2025
May 21 (Reuters) - Search engine giant Baidu ( BIDU ) on Wednesday reported its quarterly revenue rose by 3%, indicating some recovery in the Chinese advertising market. Revenue in the first quarter stood at 32.45 billion yuan ($4.50 billion), beating analysts' average estimate of 30.9 billion yuan, according to data compiled by LSEG. ($1 = 7.2067 Chinese yuan renminbi)...
Copyright 2023-2026 - www.financetom.com All Rights Reserved